Eric Youwei Wong

Deputy Director, Head of allogeneic stem cell transplantation

UTHealth

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Eric Youwei Wong is the Deputy Director and Head of Allogeneic Stem Cell Transplantation at Austin Health in Australia. His research focuses on graft-versus-host disease prophylaxis, patient outcomes in bone marrow transplant rehabilitation, and the impacts of pretransplant reviews on latent tuberculosis infection among allogeneic transplant recipients. He has contributed to several recent studies exploring treatment strategies and optimizing therapies for hematologic malignancies.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Collaborators (3)

David Ritchie

Head of BMT

AUSTRALIA

View details

Janine Trevillyan

University of Melbourne

AUSTRALIA

View details

Amit Khot

Associate Professor

University of Melbourne

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Eric Youwei Wong

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Latent Tuberculosis Infection Amongst Allogeneic Hematopoietic Stem Cell Transplant Recipients: The Impact of Routine Pretransplant Review by a Transplant Infectious Diseases Physician

Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin

Methotrexate dose modification does not impact on graft vs host disease in allograft patients given thymoglobulin prophylaxis

Rehabilitation after bone marrow transplant compared with usual care to improve patient outcomes (REBOOT): protocol for a randomised controlled trial

CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma

A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome

Outcome of an elective readmission policy in patients receiving acute myeloid leukaemia consolidation therapy and implications for an outpatient management programme

Optimizing the oral dose of cyclosporine with concomitant posaconazole post stem cell allograft

T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection

Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients

Collaborators (3)

David Ritchie

Janine Trevillyan

Amit Khot

Make your next move.